Morgan Stanley
MCRB icon

Morgan Stanley’s Seres Therapeutics MCRB Stock Holding History

Morgan Stanley’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$192K Sell
21,700
-3,426
-14% -$40.1K ﹤0.01% 5891
2025
Q4 		$374K Buy
25,126
+6,792
+37% +$118K ﹤0.01% 5664
2025
Q3 		$353K Buy
18,334
+10,496
+134% +$167K ﹤0.01% 5656
2025
Q2 		$87.1K Buy
7,838
+358
+5% +$3.15K ﹤0.01% 6183
2025
Q1 		$105K Sell
7,480
-93,183
-93% -$1.46M ﹤0.01% 5989
2024
Q4 		$1.67M Buy
100,663
+60,547
+151% +$984K ﹤0.01% 4826
2024
Q3 		$759K Buy
40,116
+31,562
+369% +$640K ﹤0.01% 5200
2024
Q2 		$124K Sell
8,554
-15,327
-64% -$256K ﹤0.01% 5884
2024
Q1 		$370K Sell
23,881
-64,653
-73% -$1.39M ﹤0.01% 5449
2023
Q4 		$2.48M Buy
88,534
+70,064
+379% +$1.84M ﹤0.01% 4805
2023
Q3 		$879K Sell
18,470
-4,589
-20% -$350K ﹤0.01% 4872
2023
Q2 		$2.21M Buy
23,059
+13,348
+137% +$1.45M ﹤0.01% 4367
2023
Q1 		$1.1M Sell
9,711
-1,235
-11% -$134K ﹤0.01% 4804
2022
Q4 		$1.23M Buy
10,946
+4,977
+83% +$667K ﹤0.01% 4747
2022
Q3 		$765K Sell
5,969
-5,263
-47% -$539K ﹤0.01% 5041
2022
Q2 		$770K Sell
11,232
-18,544
-62% -$1.6M ﹤0.01% 5187
2022
Q1 		$4.24M Buy
29,776
+2,540
+9% +$391K ﹤0.01% 3858
2021
Q4 		$4.54M Sell
27,236
-6,836
-20% -$1.09M ﹤0.01% 3820
2021
Q3 		$4.74M Buy
34,072
+2,679
+9% +$524K ﹤0.01% 3779
2021
Q2 		$15M Buy
31,393
+13,705
+77% +$5.78M ﹤0.01% 2506
2021
Q1 		$7.28M Buy
17,688
+10,133
+134% +$4.67M ﹤0.01% 3004
2020
Q4 		$3.7M Buy
7,555
+2,678
+55% +$1.57M ﹤0.01% 3587
2020
Q3 		$2.76M Sell
4,877
-166
-3% -$55.2K ﹤0.01% 3353
2020
Q2 		$480K Buy
5,043
+168
+3% +$14.7K ﹤0.01% 4623
2020
Q1 		$348K Sell
4,875
-2,319
-32% -$156K ﹤0.01% 4585
2019
Q4 		$496K Buy
7,194
+1,296
+22% +$96.1K ﹤0.01% 4925
2019
Q3 		$473K Sell
5,898
-1,247
-17% -$82.4K ﹤0.01% 4704
2019
Q2 		$460K Sell
7,145
-6,472
-48% -$614K ﹤0.01% 4648
2019
Q1 		$1.87M Buy
13,617
+4,986
+58% +$608K ﹤0.01% 3646
2018
Q4 		$780K Sell
8,631
-148
-2% -$20.7K ﹤0.01% 4472
2018
Q3 		$1.33M Buy
8,779
+468
+6% +$75.7K ﹤0.01% 4313
2018
Q2 		$1.43M Sell
8,311
-1,642
-16% -$268K ﹤0.01% 4370
2018
Q1 		$1.46M Buy
9,953
+4,522
+83% +$867K ﹤0.01% 4268
2017
Q4 		$1.1M Buy
5,431
+2,929
+117% +$602K ﹤0.01% 4475
2017
Q3 		$802K Buy
2,502
+1,127
+82% +$308K ﹤0.01% 4570
2017
Q2 		$311K Sell
1,375
-868
-39% -$178K ﹤0.01% 5089
2017
Q1 		$506K Sell
2,243
-2,398
-52% -$487K ﹤0.01% 4829
2016
Q4 		$919K Buy
4,641
+1,450
+45% +$316K ﹤0.01% 4532
2016
Q3 		$784K Buy
3,191
+1,430
+81% +$502K ﹤0.01% 4218
2016
Q2 		$1.02M Sell
1,761
-540
-23% -$317K ﹤0.01% 3952
2016
Q1 		$1.22M Buy
2,301
+613
+36% +$320K ﹤0.01% 3764
2015
Q4 		$1.19M Buy
1,688
+1,169
+225% +$768K ﹤0.01% 3933
2015
Q3 		$307K Buy
519
+394
+315% +$321K ﹤0.01% 4875
2015
Q2 		$104K Buy
+125
New +$109K ﹤0.01% 5563

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's MCRB Position: Q1 2026 in Review

Morgan Stanley reduced its Seres Therapeutics (MCRB) stake by 14% in Q1 2026, selling an estimated $40.1K and leaving 21,700 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #5891.

Morgan Stanley first reported a position in MCRB in Q2 2015 and has held it in 44 quarters since. The position peaked at $15M in Q2 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Morgan Stanley held 21,700 shares of Seres Therapeutics worth $192K as of Q1 2026.
  • Morgan Stanley sold 3,426 Seres Therapeutics shares in Q1 2026, an estimated $40.1K.
  • Seres Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5891 holding.
  • Morgan Stanley first reported a position in Seres Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • Morgan Stanley's Seres Therapeutics position peaked at $15M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.